再鼎医药(09688.HK) (ZLAB.US) 宣布,国家医疗保障局发布的2024国家医保药品目录已更新,并将公司旗下“奥凯乐”(瑞普替尼)纳入到新版国家医保药品目录当中,用于治疗ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者。另外,集团的“纽再乐”(奥马环素)静脉输注剂型及“擎乐”(瑞派替尼)在今次目录更新中成功续约,分别用于治疗患有社区获得性细菌性肺炎和急性细菌性皮肤和皮肤结构感染的...
Source Link再鼎医药(09688.HK) (ZLAB.US) 宣布,国家医疗保障局发布的2024国家医保药品目录已更新,并将公司旗下“奥凯乐”(瑞普替尼)纳入到新版国家医保药品目录当中,用于治疗ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者。另外,集团的“纽再乐”(奥马环素)静脉输注剂型及“擎乐”(瑞派替尼)在今次目录更新中成功续约,分别用于治疗患有社区获得性细菌性肺炎和急性细菌性皮肤和皮肤结构感染的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.